Department of Cellular Pathology, Royal Liverpool University Hospital, Liverpool, UK.
Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Ciberonc and Complutense University, Madrid, Spain.
ESMO Open. 2023 Aug;8(4):101587. doi: 10.1016/j.esmoop.2023.101587. Epub 2023 Jun 23.
Biomarker tests in lung cancer have been traditionally ordered by the treating oncologist upon confirmation of an appropriate pathological diagnosis. The delay this introduces prolongs yet further what is already a complex, multi-stage, pre-treatment pathway and delays the start of first-line systemic treatment, which is crucially informed by the results of such analysis. Reflex testing, in which the responsibility for testing for an agreed range of biomarkers lies with the pathologist, has been shown to standardise and expedite the process. Twelve experts discussed the rationale and considerations for implementing reflex testing as standard clinical practice.
生物标志物检测在肺癌中的应用一直以来都是在病理诊断确认后由治疗肿瘤学家进行的。这种方法引入的延迟进一步延长了本已复杂的、多阶段的治疗前途径，并延迟了一线系统治疗的开始，而这一治疗的关键是基于此类分析的结果。基于病理学家的职责进行一系列约定生物标志物检测的反射性检测已经显示出标准化和加速这一过程的效果。十二位专家讨论了将反射性检测作为标准临床实践的实施的基本原理和考虑因素。
